These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21725616)

  • 1. Cilengitide inhibits metastatic bone colonization in a nude rat model.
    Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
    Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.
    Bäuerle T; Komljenovic D; Merz M; Berger MR; Goodman SL; Semmler W
    Int J Cancer; 2011 May; 128(10):2453-62. PubMed ID: 20648558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein.
    Bäuerle T; Peterschmitt J; Hilbig H; Kiessling F; Armbruster FP; Berger MR
    Int J Oncol; 2006 Mar; 28(3):573-83. PubMed ID: 16465361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.
    Bretschi M; Cheng C; Witt H; Dimitrakopoulou-Strauss A; Strauss LG; Semmler W; Bäuerle T
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):573-83. PubMed ID: 23229276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
    Zhao Y; Bachelier R; Treilleux I; Pujuguet P; Peyruchaud O; Baron R; Clément-Lacroix P; Clézardin P
    Cancer Res; 2007 Jun; 67(12):5821-30. PubMed ID: 17575150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
    Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
    Bäuerle T; Merz M; Komljenovic D; Zwick S; Semmler W
    Clin Cancer Res; 2010 Jun; 16(12):3215-25. PubMed ID: 20530698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
    Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cilengitide in osteoclast maturation and behavior.
    Chillà A; Bianconi D; Geetha N; Dorda A; Poettler M; Unseld M; Sykoutri D; Redlich K; Zielinski CC; Prager GW
    Exp Cell Res; 2015 Sep; 337(1):68-75. PubMed ID: 26209605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-modal imaging of angiogenesis in a nude rat model of breast cancer bone metastasis using magnetic resonance imaging, volumetric computed tomography and ultrasound.
    Bäuerle T; Komljenovic D; Berger MR; Semmler W
    J Vis Exp; 2012 Aug; (66):e4178. PubMed ID: 22929330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiofrequency ablation of experimental bone metastases in nude rats.
    Proschek D; Mack MG; Kurth AA; Proschek P; Martin B; Hansmann ML; Vogl TJ
    Anticancer Res; 2008; 28(2A):879-85. PubMed ID: 18507032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases.
    Merz M; Komljenovic D; Semmler W; Bäuerle T
    Invest Radiol; 2012 Jul; 47(7):422-9. PubMed ID: 22659593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG.
    Cheng C; Komljenovic D; Pan L; Dimitrakopoulou-Strauss A; Strauss L; Bäuerle T
    Hell J Nucl Med; 2011; 14(1):15-20. PubMed ID: 21512659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
    J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.